In:
Journal of Cardiovascular Electrophysiology, Wiley, Vol. 20, No. 6 ( 2009-06), p. 658-662
Abstract:
Background: Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in patients with heart failure (HF), lowered LV ejection fraction, and wide QRS. However, many patients (≤40%) do not respond to this form of pacing. TRUST CRT is a prospective, single‐center, randomized, single‐blind, parallel, and controlled study that has been designed to treat patients with moderate to severe HF (NYHA III‐IV), QRS ≥120 ms, sinus rhythm, LV dysfunction (EF ≤ 35%), and signs of mechanical dyssynchrony. Objective: The primary objective will evaluate the 6‐month's combined endpoint of alive status, freedom from hospitalization for HF or heart transplantation, relative ≥10% increase in LV ejection fraction, ≥10% in peak oxygen consumption, and ≥10% in 6‐minute walking distance. Methods: Patients with HF receiving optimal pharmacotherapy, with LV dysfunction, mechanical dyssynchrony, wide QRS and sinus rhythm will be randomized in a 1: 1 fashion to standard or triple‐site CRT‐D. Patients will be followed for 1 week, 1, 3, and 6 months during a blind phase, then every 6 months until study completion. One hundred patients will be enrolled by the study center. Conclusions: TRUST CRT is a randomized, clinical trial in CRT candidates to evaluate the effectiveness of triple‐site pacing versus standard resynchronization in patients with HF.
Type of Medium:
Online Resource
ISSN:
1045-3873
,
1540-8167
DOI:
10.1111/jce.2009.20.issue-6
DOI:
10.1111/j.1540-8167.2008.01394.x
Language:
English
Publisher:
Wiley
Publication Date:
2009
detail.hit.zdb_id:
2037519-0
Bookmarklink
